(IPOScoop has No Call on this initial public offering. Please see this statement in the prospectus: “Until recently, our Ordinary Shares traded on the Australian Securities Exchange operated by ASX Ltd. (or ASX), under the symbol “GMV.” On October 22, 2020, our Ordinary Shares were voluntarily delisted from the ASX. We have been approved to list the Ordinary Shares on the Nasdaq Global Market under the symbol “GMVD”, subject to notice of issuance. No assurance can be given that an active trading market for our Ordinary Shares will develop.”)

We are an early commercial stage healthcare company engaged in the development of next generation mobile health (or mHealth) and telemedicine solutions and monitoring service platforms. We believe we are at the forefront of the digital health revolution in developing the next generation mobile technologies and services that are designed to empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes.

(Note: G Medical Innovations Holdings re-filed its IPO on June 9, 2021, as a unit offering – 2.5 million units at $5 to $7 each – to raise $15 million, according to an F-1/A filing. Each unit consists of one ordinary share and one warrant, exercisable at 125 percent of the IPO price. The IPO previously consisted of 3 million shares at $5 to $7 each to raise $18 million, if priced at the mid-point. The IPO’s size was cut by 17 percent, in terms of the estimated proceeds. In the F-1/A filing dated June 8, 2021, G Medical Innovations also switched underwriters to Kingswood Capital Markets as the sole book-runner from ThinkEquity.)